Biosimilar Monoclonal Antibody Market Report

Global Biosimilar Monoclonal Antibody Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：147
  • REPORT CODE：GMM860993
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Biosimilar Monoclonal Antibody market report explains the definition, types, applications, major countries, and major players of the Biosimilar Monoclonal Antibody market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Hospira

    • 3SBio

    • Reddy's Laboratories

    • Biocon

    • AET Biotech

    • Alvartis

    • Accord Healthcare

    • Allergan

    • Amgen

    • Celltrion

    By Type:

    • Synthetic Chemicals

    • Biopharmaceuticals

    • Others

    By End-User:

    • Chronic & Autoimmune Diseases

    • Oncology

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Biosimilar Monoclonal Antibody Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Biosimilar Monoclonal Antibody Outlook to 2028- Original Forecasts

    • 2.2 Biosimilar Monoclonal Antibody Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Biosimilar Monoclonal Antibody Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Biosimilar Monoclonal Antibody Market- Recent Developments

    • 6.1 Biosimilar Monoclonal Antibody Market News and Developments

    • 6.2 Biosimilar Monoclonal Antibody Market Deals Landscape

    7 Biosimilar Monoclonal Antibody Raw Materials and Cost Structure Analysis

    • 7.1 Biosimilar Monoclonal Antibody Key Raw Materials

    • 7.2 Biosimilar Monoclonal Antibody Price Trend of Key Raw Materials

    • 7.3 Biosimilar Monoclonal Antibody Key Suppliers of Raw Materials

    • 7.4 Biosimilar Monoclonal Antibody Market Concentration Rate of Raw Materials

    • 7.5 Biosimilar Monoclonal Antibody Cost Structure Analysis

      • 7.5.1 Biosimilar Monoclonal Antibody Raw Materials Analysis

      • 7.5.2 Biosimilar Monoclonal Antibody Labor Cost Analysis

      • 7.5.3 Biosimilar Monoclonal Antibody Manufacturing Expenses Analysis

    8 Global Biosimilar Monoclonal Antibody Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Biosimilar Monoclonal Antibody Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Biosimilar Monoclonal Antibody Export by Region (Top 10 Countries) (2017-2028)

    9 Global Biosimilar Monoclonal Antibody Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilar Monoclonal Antibody Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Synthetic Chemicals Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Biopharmaceuticals Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilar Monoclonal Antibody Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Chronic & Autoimmune Diseases Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Biosimilar Monoclonal Antibody Market Analysis and Outlook till 2022

    • 10.1 Global Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.2.2 Canada Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.2.3 Mexico Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.2 UK Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.3 Spain Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.4 Belgium Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.5 France Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.6 Italy Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.7 Denmark Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.8 Finland Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.9 Norway Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.10 Sweden Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.11 Poland Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.12 Russia Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.3.13 Turkey Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.2 Japan Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.3 India Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.4 South Korea Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.5 Pakistan Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.6 Bangladesh Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.7 Indonesia Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.8 Thailand Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.9 Singapore Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.10 Malaysia Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.11 Philippines Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.4.12 Vietnam Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.2 Colombia Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.3 Chile Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.4 Argentina Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.5 Venezuela Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.6 Peru Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.7 Puerto Rico Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.5.8 Ecuador Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.6.2 Kuwait Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.6.3 Oman Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.6.4 Qatar Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.7.2 South Africa Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.7.3 Egypt Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.7.4 Algeria Biosimilar Monoclonal Antibody Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Biosimilar Monoclonal Antibody Consumption (2017-2022)

      • 10.8.2 New Zealand Biosimilar Monoclonal Antibody Consumption (2017-2022)

    11 Global Biosimilar Monoclonal Antibody Competitive Analysis

    • 11.1 Hospira

      • 11.1.1 Hospira Company Details

      • 11.1.2 Hospira Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Hospira Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.1.4 Hospira Biosimilar Monoclonal Antibody Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 3SBio

      • 11.2.1 3SBio Company Details

      • 11.2.2 3SBio Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 3SBio Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.2.4 3SBio Biosimilar Monoclonal Antibody Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Reddy's Laboratories

      • 11.3.1 Reddy's Laboratories Company Details

      • 11.3.2 Reddy's Laboratories Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Reddy's Laboratories Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.3.4 Reddy's Laboratories Biosimilar Monoclonal Antibody Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Biocon

      • 11.4.1 Biocon Company Details

      • 11.4.2 Biocon Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Biocon Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.4.4 Biocon Biosimilar Monoclonal Antibody Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 AET Biotech

      • 11.5.1 AET Biotech Company Details

      • 11.5.2 AET Biotech Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 AET Biotech Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.5.4 AET Biotech Biosimilar Monoclonal Antibody Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Alvartis

      • 11.6.1 Alvartis Company Details

      • 11.6.2 Alvartis Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Alvartis Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.6.4 Alvartis Biosimilar Monoclonal Antibody Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Accord Healthcare

      • 11.7.1 Accord Healthcare Company Details

      • 11.7.2 Accord Healthcare Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Accord Healthcare Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.7.4 Accord Healthcare Biosimilar Monoclonal Antibody Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Allergan

      • 11.8.1 Allergan Company Details

      • 11.8.2 Allergan Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Allergan Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.8.4 Allergan Biosimilar Monoclonal Antibody Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Amgen

      • 11.9.1 Amgen Company Details

      • 11.9.2 Amgen Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Amgen Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.9.4 Amgen Biosimilar Monoclonal Antibody Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Celltrion

      • 11.10.1 Celltrion Company Details

      • 11.10.2 Celltrion Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Celltrion Biosimilar Monoclonal Antibody Main Business and Markets Served

      • 11.10.4 Celltrion Biosimilar Monoclonal Antibody Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Biosimilar Monoclonal Antibody Market Outlook by Types and Applications to 2028

    • 12.1 Global Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Synthetic Chemicals Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Biopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Chronic & Autoimmune Diseases Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Biosimilar Monoclonal Antibody Market Analysis and Outlook to 2028

    • 13.1 Global Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.2.2 Canada Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.2 UK Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.3 Spain Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.5 France Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.6 Italy Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.8 Finland Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.9 Norway Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.11 Poland Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.12 Russia Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.2 Japan Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.3 India Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.3 Chile Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.6 Peru Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.6.3 Oman Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Biosimilar Monoclonal Antibody Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Biosimilar Monoclonal Antibody

    • Figure of Biosimilar Monoclonal Antibody Picture

    • Table Global Biosimilar Monoclonal Antibody Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Biosimilar Monoclonal Antibody Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Synthetic Chemicals Consumption and Growth Rate (2017-2022)

    • Figure Global Biopharmaceuticals Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Chronic & Autoimmune Diseases Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Table North America Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure United States Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Canada Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Mexico Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure Germany Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure UK Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Spain Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Belgium Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure France Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Italy Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Denmark Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Finland Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Norway Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Sweden Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Poland Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Russia Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Turkey Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table APAC Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure China Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Thailand Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Singapore Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Philippines Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table South America Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure Brazil Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Colombia Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Chile Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Argentina Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Peru Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table GCC Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure Bahrain Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Oman Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Qatar Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table Africa Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure Nigeria Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure South Africa Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Egypt Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure Algeria Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table Oceania Biosimilar Monoclonal Antibody Consumption by Country (2017-2022)

    • Figure Australia Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Biosimilar Monoclonal Antibody Consumption and Growth Rate (2017-2022)

    • Table Hospira Company Details

    • Table Hospira Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hospira Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Hospira Biosimilar Monoclonal Antibody Product Portfolio

    • Table 3SBio Company Details

    • Table 3SBio Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table 3SBio Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table 3SBio Biosimilar Monoclonal Antibody Product Portfolio

    • Table Reddy's Laboratories Company Details

    • Table Reddy's Laboratories Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Reddy's Laboratories Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Reddy's Laboratories Biosimilar Monoclonal Antibody Product Portfolio

    • Table Biocon Company Details

    • Table Biocon Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Biocon Biosimilar Monoclonal Antibody Product Portfolio

    • Table AET Biotech Company Details

    • Table AET Biotech Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table AET Biotech Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table AET Biotech Biosimilar Monoclonal Antibody Product Portfolio

    • Table Alvartis Company Details

    • Table Alvartis Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alvartis Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Alvartis Biosimilar Monoclonal Antibody Product Portfolio

    • Table Accord Healthcare Company Details

    • Table Accord Healthcare Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Accord Healthcare Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Accord Healthcare Biosimilar Monoclonal Antibody Product Portfolio

    • Table Allergan Company Details

    • Table Allergan Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Allergan Biosimilar Monoclonal Antibody Product Portfolio

    • Table Amgen Company Details

    • Table Amgen Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Amgen Biosimilar Monoclonal Antibody Product Portfolio

    • Table Celltrion Company Details

    • Table Celltrion Biosimilar Monoclonal Antibody Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Biosimilar Monoclonal Antibody Main Business and Markets Served

    • Table Celltrion Biosimilar Monoclonal Antibody Product Portfolio

    • Figure Global Synthetic Chemicals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biopharmaceuticals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chronic & Autoimmune Diseases Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Table North America Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure Germany Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure China Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure Brazil Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Biosimilar Monoclonal Antibody Consumption Forecast by Country (2022-2028)

    • Figure Australia Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Biosimilar Monoclonal Antibody Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US